Skip to main content

Published locations for Surrogate endpoints acceptable in AML trials, says FDA

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Surrogate endpoints acceptable in AML trials, says FDA

User login

  • Reset your password
  • /content/surrogate-endpoints-acceptable-aml-trials-says-fda
  • /hematologynews/article/251316/aml/surrogate-endpoints-acceptable-aml-trials-says-fda
  • /hematology-oncology/article/251316/aml/surrogate-endpoints-acceptable-aml-trials-says-fda